Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via Google Scholar



	Articles by Dysken, M. W.
	Articles by Kuskowski, M.
	Search for Related Content



	PubMed Citation
	Articles by Dysken, M. W.
	Articles by Kuskowski, M.

J Neuropsychiatry Clin Neurosci 1989; 1:249-252
Copyright © 1989 by American Neuropsychiatric Association

REGULAR ARTICLES

Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia

MW Dysken, R Katz, F Stallone and M Kuskowski
Minneapolis Veterans Administration Medical Center, MN.

Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi- infarct dementia (MID) and primary degenerative dementia (PDD). Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.

Get information about faster international access.